🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "significant breakthrough" in the effort against increasingly resistant strains of the infection, according to scientists.

A Worldwide Public Health Issue

The sexually transmitted infection are on the rise worldwide, with figures suggesting more than 82 million instances each year. Especially elevated rates are seen in Africa and countries within the WHO's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary development in the face of increasing worldwide cases, escalating drug resistance and the extremely scarce available drugs presently on offer.”

Public health authorities are deeply concerned about the increase in drug-resistant strains. The WHO has listed it as a "priority pathogen". A tracking program found that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Receive Approval

One new antibiotic, marketed under the name Nuzolvence, was cleared by the American regulatory agency in mid-December for use against gonorrhoea. This STI can lead to major issues, including infertility. Researchers believe that focused deployment of this new drug will help delay the spread of drug resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This medication, which is employed against UTIs, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin emerged from a unique collaborative effort for medication research. The non-profit organisation GARDP worked alongside the drug firm Innoviva to develop it.

“This authorization represents a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Testing Data and Global Access

According to data detailed in a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the typical regimen, which uses a dual-drug approach. The research included hundreds of patients from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the ability to register and commercialise the drug in many low-income and middle-income countries.

Clinicians on the front lines have expressed positive views. Access to a one-pill regimen of this kind is hailed as a "game-changer" for gonorrhoea control. This is viewed as crucial to lessen the impact of the disease for individuals and to stop the proliferation of extremely resistant gonorrhoea worldwide.